WO2023277432A1 - 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법 - Google Patents
재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법 Download PDFInfo
- Publication number
- WO2023277432A1 WO2023277432A1 PCT/KR2022/008793 KR2022008793W WO2023277432A1 WO 2023277432 A1 WO2023277432 A1 WO 2023277432A1 KR 2022008793 W KR2022008793 W KR 2022008793W WO 2023277432 A1 WO2023277432 A1 WO 2023277432A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- botulinum toxin
- toxin type
- light chain
- recombinant
- type
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title claims abstract description 253
- 229940053031 botulinum toxin Drugs 0.000 title claims abstract description 245
- 108010057266 Type A Botulinum Toxins Proteins 0.000 title claims abstract description 140
- 229940094657 botulinum toxin type a Drugs 0.000 title claims abstract description 134
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims abstract description 32
- 150000001413 amino acids Chemical class 0.000 claims description 40
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- 239000000654 additive Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 208000032544 Cicatrix Diseases 0.000 claims description 10
- 206010044074 Torticollis Diseases 0.000 claims description 10
- 206010005159 blepharospasm Diseases 0.000 claims description 10
- 230000000744 blepharospasm Effects 0.000 claims description 10
- 231100000241 scar Toxicity 0.000 claims description 10
- 230000037387 scars Effects 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 230000000996 additive effect Effects 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 8
- 230000037303 wrinkles Effects 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 5
- 208000014094 Dystonic disease Diseases 0.000 claims description 5
- 206010063006 Facial spasm Diseases 0.000 claims description 5
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 5
- 208000002260 Keloid Diseases 0.000 claims description 5
- 208000019695 Migraine disease Diseases 0.000 claims description 5
- 206010067672 Spasmodic dysphonia Diseases 0.000 claims description 5
- 206010000496 acne Diseases 0.000 claims description 5
- 201000002866 cervical dystonia Diseases 0.000 claims description 5
- 208000010118 dystonia Diseases 0.000 claims description 5
- 230000037315 hyperhidrosis Effects 0.000 claims description 5
- 208000018197 inherited torticollis Diseases 0.000 claims description 5
- 210000001117 keloid Anatomy 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 239000011148 porous material Substances 0.000 claims description 5
- 108010074523 rimabotulinumtoxinB Proteins 0.000 claims description 5
- 201000002849 spasmodic dystonia Diseases 0.000 claims description 5
- 108700017751 botulinum toxin type C Proteins 0.000 claims description 4
- 108010069022 botulinum toxin type D Proteins 0.000 claims description 4
- 108010069023 botulinum toxin type E Proteins 0.000 claims description 4
- 108010069038 botulinum toxin type F Proteins 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 3
- 208000003251 Pruritus Diseases 0.000 claims description 3
- 210000000436 anus Anatomy 0.000 claims description 3
- 108010069071 botulinum toxin type G Proteins 0.000 claims description 3
- 244000221110 common millet Species 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 206010068172 Anal pruritus Diseases 0.000 claims description 2
- 208000009544 Pruritus Ani Diseases 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 150000008040 ionic compounds Chemical class 0.000 claims description 2
- 239000008176 lyophilized powder Substances 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 229940071643 prefilled syringe Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 150000005846 sugar alcohols Chemical class 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 206010023330 Keloid scar Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 239000011814 protection agent Substances 0.000 claims 1
- 108700014852 coretox Proteins 0.000 description 54
- 210000003205 muscle Anatomy 0.000 description 54
- 244000309466 calf Species 0.000 description 44
- 235000001014 amino acid Nutrition 0.000 description 28
- 229940024606 amino acid Drugs 0.000 description 28
- 238000012360 testing method Methods 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 25
- 241000700159 Rattus Species 0.000 description 18
- 238000005259 measurement Methods 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 238000006467 substitution reaction Methods 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 210000003371 toe Anatomy 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 108700012359 toxins Proteins 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- -1 DTT Chemical compound 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 5
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000036982 action potential Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 238000002849 thermal shift Methods 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 3
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 241000193155 Clostridium botulinum Species 0.000 description 2
- 238000011537 Coomassie blue staining Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010059378 Endopeptidases Proteins 0.000 description 2
- 102000005593 Endopeptidases Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 238000003505 heat denaturation Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229960004184 ketamine hydrochloride Drugs 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000003957 neurotransmitter release Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000006384 Soluble N-Ethylmaleimide-Sensitive Factor Attachment Proteins Human genes 0.000 description 1
- 108010019040 Soluble N-Ethylmaleimide-Sensitive Factor Attachment Proteins Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000000454 fifth toe Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- JKKCSFJSULZNDN-UHFFFAOYSA-N gonyautoxin v Chemical compound N=C1NC(COC(=O)NS(O)(=O)=O)C2NC(=N)NC22C(O)(O)CCN21 JKKCSFJSULZNDN-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940112646 myobloc Drugs 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000001422 normality test Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6416—Metalloendopeptidases (3.4.24)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present disclosure relates to recombinant botulinum toxins, and more particularly to recombinant botulinum toxin type A light chains, recombinant botulinum toxins, and compositions, uses and methods related thereto.
- Botulinum Toxin is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species. Botulinum toxin blocks the release of the neurotransmitter acetylcholine from the axon terminals of the neuromuscular junction.
- Botulinum toxin is synthesized as a 150 kDa double-chain protein consisting of a 100 kDa heavy chain and a 50 kDa light chain linked by disulfide bonds.
- the heavy chain is further divided into an N-terminal domain (Hn), which helps translocate the light chain to the cell's cytosol, and a C-terminal domain (Hc), which recognizes and binds to cell surface receptors on nerve cells. .
- Hn N-terminal domain
- Hc C-terminal domain
- the light chain specifically hydrolyzes a portion of the soluble NSF-attachment protein receptor (SNARE) to inactivate neurotransmitter release.
- SNARE soluble NSF-attachment protein receptor
- Botulinum toxins are divided into seven serotypes (botulinum toxin type A, botulinum toxin type B, botulinum toxin type C, botulinum toxin type D, botulinum toxin type E, botulinum toxin type F and botulinum toxin type G), which are It is further subdivided into subtypes based on variance.
- botulinum toxin type A1 has been extensively studied at the molecular level, preclinical, and clinical stages, and is currently widely used in the pharmaceutical industry.
- botulinum toxin type A subtypes it is difficult to isolate the purified toxin, so there are few studies or reports on pharmacological characteristics.
- botulinum toxin type A subtypes have been characterized biochemically, cellularly and in vivo.
- various in vitro and in vivo studies on botulinum toxin type A subtypes have revealed properties that are distinct from botulinum toxin type A1 in terms of mechanisms such as potency, intracellular movement, and persistence.
- properties at the in vitro level have been reported for botulinum toxin types A7 and A8.
- International Publication WO2018/132423 discloses a botulinum neurotoxin mixture comprising a light chain peptide of subtype A 1 of botulinum neurotoxin type A and a heavy chain peptide of subtype 2 of botulinum neurotoxin for improved potency, cell entry kinetics, and duration of action, and including the same A pharmaceutical composition is disclosed.
- International Publication WO2017/214447 discloses botulinum toxin B1 in which the heavy chain sequence is recombined to maintain the same level of toxin activity at a lower dose.
- Another object of the present disclosure is to provide a composition related to the recombinant botulinum toxin.
- Another object of the present disclosure is to provide a use of a composition related to the recombinant botulinum toxin.
- Another object of the present disclosure is to provide a method for improving or treating a disease, including administering a composition related to the recombinant botulinum toxin to a subject.
- Another object of the present disclosure is to provide a wild-type botulinum toxin type A light chain, a recombinant botulinum toxin type A light chain having increased potency or half-life compared to a wild-type botulinum toxin containing the same, and a method for preparing a recombinant botulinum toxin comprising the same. It is to do.
- One aspect of the present disclosure is that the sequence of the third domain among the first, second, third, and fourth domains of a botulinum toxin type A light chain other than botulinum toxin type A4 is the sequence of the third domain of botulinum toxin type A4 or a variant thereof.
- a substituted, recombinant botulinum toxin type A light chain is provided.
- Another aspect of the present disclosure is that the sequence of the fourth domain of the first, second, third, and fourth domains of the recombinant botulinum toxin type A light chain is further substituted with the sequence of the fourth domain of botulinum toxin type A4 or a variant thereof. a recombinant botulinum toxin type A light chain.
- Another aspect of the present disclosure provides a recombinant botulinum toxin comprising the recombinant botulinum toxin type A light chain and a botulinum toxin heavy chain.
- compositions comprising the recombinant botulinum toxin and a pharmaceutically acceptable excipient or additive.
- Another aspect of the present disclosure provides a use for ameliorating or treating a disease by administering to a subject a composition comprising the recombinant botulinum toxin and a pharmaceutically acceptable excipient or additive.
- sequence of a third domain of the first, second, third, and fourth domains of a botulinum toxin type A light chain other than botulinum toxin type A4 is a sequence of the third domain of botulinum toxin type A4 or a variant thereof.
- a method for preparing a recombinant botulinum toxin type A light chain having an increased effect or half-life compared to wild-type botulinum toxin type A light chain comprising the step of substituting with .
- Another aspect of the present disclosure is that the sequence of the fourth domain of the first, second, third, and fourth domains of the recombinant botulinum toxin type A light chain is further substituted with the sequence of the fourth domain of botulinum toxin type A4 or a variant thereof.
- a method for producing a recombinant botulinum toxin type A light chain having an increased potency or half-life compared to a wild-type botulinum toxin type A light chain comprising the steps of:
- Another aspect of the present disclosure provides a method for preparing a recombinant botulinum toxin having an increased potency or half-life compared to a wild-type botulinum toxin comprising the recombinant botulinum toxin type A light chain and a botulinum toxin heavy chain.
- a recombinant botulinum toxin type A light chain a recombinant botulinum toxin, and a composition, use, and method related thereto, which increase patient convenience by increasing potency and half-life, and enable customized treatment for indications.
- 1A shows a sequence comparison (ESPript3.0, Robert and Gouet, 2014) of botulinum toxin type A1 light chain (GenBank: CAL82360.1), and botulinum toxin type A4 light chain (GenBank: ACQ51417.1).
- the boundaries and starting points of each domain for domain substitution are indicated by arrows and boxes, and the table below shows the sequence ranges of each domain and the results of amino acid identity analysis between the two sequences.
- FIG. 1B shows structural information on domains obtained by dividing a botulinum toxin type A1 light chain and a botulinum toxin type A4 light chain, showing differences in amino acid sequences and functional characteristics of each domain.
- FIG. 1C is a schematic diagram showing a combination of a recombinant botulinum toxin type A light chain in which domains of a botulinum toxin type A1 light chain and a botulinum toxin type A4 light chain are substituted.
- 2a is an SDS-PAGE analysis result of a domain-substituted and purified recombinant botulinum toxin type A light chain.
- FIG. 2B is a result of confirming the site hydrolyzed by the recombinant botulinum toxin type A light chain in which the domain of Clover-SNAP25-mRuby2 (137-206) is substituted.
- the domain-substituted recombinant botulinum toxin type A light chain was hydrolyzed in the presence of Samples were analyzed via SDS-PAGE and Coomassie Blue staining.
- FIG. 3 is a graph showing the thermal stability of a recombinant botulinum toxin type A light chain having domain substitutions.
- the table below shows the dissolution temperature of each domain substituted recombinant botulinum toxin light chain.
- FIG. 4 shows the result of endopeptidase assay of the recombinant botulinum toxin type A light chain in which the domain was substituted. Comparing the titers of the domain-substituted recombinant botulinum toxin type A light chain and the wild-type botulinum toxin type A light chain, pBT103 showed titers similar to those of the wild type, with pBT112 exhibiting 1.73-fold, pBT113-1.49-fold, pBT114-1.3-fold, and pBT115 titers. increased by 1.55 times.
- FIG. 5 is an SDS-PAGE analysis result of a purified product of a recombinant botulinum toxin type A light chain in which the light chain of botulinum toxin type A is substituted with a third domain of another botulinum toxin type A subtype (FIG. 5a) and thermal stability analysis. This is one result (Fig. 5b).
- the melting point of each recombinant botulinum toxin type A light chain is shown in the table below. Thermal stability was most improved when the third domain of the botulinum toxin type A4 light chain was introduced into the botulinum toxin type A light chain.
- FIG. 6a is a schematic diagram showing the construction of a recombinant botulinum toxin comprising a domain-substituted recombinant botulinum toxin type A light chain.
- 6B is a result of SDS-PAGE analysis of a purified product of a recombinant botulinum toxin into which a domain-substituted recombinant botulinum toxin type A light chain was introduced, under reducing conditions.
- the recombinant botulinum toxin was purified in a 150 kd form without impurities and then analyzed by SDS-PAGE under reducing conditions.
- FIG. 7a is a graph showing changes in DAS levels over time after administration of Coretox (botulinum toxin type A product) and recombinant botulinum toxin (pBT142) to the right calf muscle at doses of 1.2, 4, and 12 U/kg, respectively, in rats. to be. DAS values on each measurement day were analyzed using the Mann-Whitney test. (*p ⁇ 0.05)
- Figure 7b shows the trend line for the highest DAS score and the calculated DAS ED50 at each dose after Coretox and recombinant botulinum toxin (pBT142) were administered to the right calf muscle at doses of 1.2, 4, and 12 U/kg, respectively, in rats. it's a graph
- 7C is a graph showing changes in CMAP levels over time after administration of Coretox and recombinant botulinum toxin (pBT142) to the right calf muscle at a dose of 12 U/kg in rats.
- the results of analysis using a two-tailed t-test for the CMAP values of Coretox and recombinant botulinum toxin (pBT142) on each measurement day are shown. (*p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001)
- 7d is a graph showing changes in DAS levels over time after administration of Coretox and recombinant botulinum toxin (pBT147) to the right calf muscle at doses of 1.2, 4, and 12 U/kg, respectively, in rats. DAS values on each measurement day were analyzed using the Mann-Whitney test. (*p ⁇ 0.05, **p ⁇ 0.01)
- Figure 7e shows the trend line for the highest DAS score and the calculated DAS ED50 at each dose after Coretox and recombinant botulinum toxin (pBT147) were administered to the right calf muscle at doses of 1.2, 4, and 12 U/kg, respectively, in rats. it's a graph
- 7f is a graph showing changes in CMAP levels over time after administration of Coretox and recombinant botulinum toxin (pBT147) to the right calf muscle at a dose of 12 U/kg, respectively, in rats.
- the results of analysis using a two-tailed t-test for the CMAP values of Coretox and recombinant botulinum toxin (pBT147) on each measurement day are shown. (*p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001)
- FIG 8a shows the time course of DAS levels after administration of Coretox (botulinum toxin type A product) and recombinant botulinum toxin (pBT142, and pBT147) to the right calf muscle at doses of 1.2, 4, 12, and 40 U/kg, respectively, in mice. It is a graph showing the change. DAS values on each measurement day were analyzed using the Mann-Whitney test. (*p ⁇ 0.05)
- 8B shows trend lines and calculations for the highest DAS scores at each dose after administration of Coretox and recombinant botulinum toxin (pBT142, and pBT147) to the right calf muscle at doses of 1.2, 4, 12, and 40 U/kg, respectively, in mice. It is a graph showing DAS ED50.
- 8C is a graph showing changes in CMAP levels over time after administration of Coretox and recombinant botulinum toxin (pBT142, and pBT147) to the right calf muscle at a dose of 12 U/kg, respectively, in mice.
- the CMAP values of Coretox and recombinant botulinum toxin (pBT142, and pBT147) were analyzed using a two-tailed t-test. (*p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001)
- Example 1 Domain substitution of botulinum toxin type A light chain
- botulinum toxin type A1 light chain and the botulinum toxin type A4 light chain four domains of the botulinum toxin type A1 light chain and botulinum toxin type A4 light chain genes were substituted in order to confirm which domains affect protein stability.
- Example 2 Expression and purification of domain-substituted botulinum toxin type A light chain
- Example 14 types of recombinant botulinum toxin type A light chains were prepared.
- the prepared recombinant expression vector was introduced into BL21(DE3) cells, a type of E.coli, to induce expression of the domain-substituted recombinant botulinum toxin type A light chain. Expression was induced with IPTG ((Isopropyl ⁇ -D-1-thiogalactopyranoside), and the final concentration was used to be 0.5 mM. That is, after adding 0.5 ml of 1M IPTG to 1 L of liquid medium, at 37 ° C.
- BL21 (DE3) cells cultured at 18 ° C for about 18 hours were centrifuged at 4,000 rpm for 10 minutes to precipitate the cells
- the medium of the supernatant was removed, and the precipitated cells were mixed with A buffer (20 mM Tris-HCl, 300 mM NaCl).
- a buffer (20 mM Tris-HCl, 300 mM NaCl).
- the cells were disrupted on ice with an ultrasonic disperser at 2 pulses/1 pause and 35% power for 20 minutes.
- the amino acid sequences of the recombinant botulinum toxin type A light chain were isolated from pBT102 (SEQ ID NO: 18), pBT103 (SEQ ID NO: 19), pBT104 (SEQ ID NO: 20), pBT105 (SEQ ID NO: 21), and pBT106 (SEQ ID NO: 21), respectively. No.
- Test Example 1 Thermal stability evaluation of domain substituted botulinum toxin type A light chain
- the thermal stability of the recombinant botulinum toxin type A light chain in which the domain was substituted was compared.
- evaluation of the middle temperature of heat denaturation (Tm) was performed, and generally, a high temperature of middle heat denaturation is preferable.
- the thermostability of each domain-substituted recombinant botulinum toxin type A light chain was measured using a thermal shift assay (PTS).
- a thermal shift assay was performed using a Protein Thermal Shift Dye Kit (Catalog No. 4461146, Applied Biosystems) according to the manufacturer's method.
- each recombinant botulinum toxin type A light chain was mixed with protein thermal shift die and buffer to make 20 ⁇ l, and then in RT-PCR (C1000 thermal cycler equipped with a CFX96 optical reaction module, Bio-Rad) at 20 ° C. ROX signal was confirmed up to 95 °C while increasing the temperature by 1 °C per 60 seconds from . Based on the melting curve, the melting temperature (Tm) of each recombinant botulinum toxin light chain was determined. The melting point of each recombinant botulinum toxin type A light chain in which the domain was substituted is shown in FIG. 3 .
- Test Example 2 Potency evaluation of domain substituted botulinum toxin type A light chain
- an enzyme-linked immunosorbent assay (ELISA)-based endopeptidase assay was performed. First, after diluting the GST-SNAP25 (137-206) substrate to a final concentration of 2 ⁇ g/mL, 100 ⁇ L per well was added to a 96-well plate and reacted at 4° C. for 16 hours. After preparing by dissolving 2% skim milk in PBST (Phosphate Buffered Saline with Tween), 200 ⁇ l was added to wells coated with the substrate and reacted at 25° C. for 1 hour. After the reaction, wash well No.
- PBST Phosphate Buffered Saline with Tween
- Toxin Assay Buffer reaction buffer containing HEPES, DTT, zinc sulfate, and Tween-20
- STD standard sample
- domain-substituted recombinant botulinum toxin type A light chain samples target concentration: 4 U/mL
- the measured titer of was obtained.
- the recovery rate of the recombinant botulinum toxin type A light chain sample in which the domain was substituted was calculated using the calculated titer and target concentration to confirm the recovery rate against the target concentration, and the results are shown in FIG. 4 . As shown in FIG.
- pBT103 (SEQ ID NO: 19) showed a similar potency to that of the wild-type botulinum toxin type A1 light chain, and pBT114 (SEQ ID NO: 30) and pBT115 (SEQ ID NO: 31) showed a 1.5-fold increase in titer.
- Comparative Example 1 Expression, purification and thermal stability evaluation of recombinant botulinum toxin type A light chain substituted with light chain third domain of another botulinum toxin type A subtype
- botulinum toxin type A2 A5, A7, and A8 light chains that are botulinum toxin type A other than botulinum toxin type A4 light chains
- thermal stability was compared.
- a recombinant botulinum toxin type A light chain in which the third domain was substituted four recombinant botulinum toxin type A light chains were purified according to the purification method of Example 2, and the light chain 3 domain of each botulinum toxin type A subtype was substituted.
- the recombinant botulinum toxin type A light chain was transformed into E.coli It was cloned into pET28a, an expression vector.
- pBT158 (SEQ ID NO: 32) is a vector substituted with the third domain of the botulinum toxin type A2 light chain
- pBT160 (SEQ ID NO: 33) is a vector substituted with the third domain of the botulinum toxin type A5 light chain
- the third domain of the botulinum toxin type A7 light chain The vector substituted with the domain was named pBT161 (SEQ ID NO: 34)
- the vector substituted with the third domain of the botulinum toxin type A8 light chain was named pBT162 (SEQ ID NO: 35).
- Each recombinant botulinum toxin type A light chain was purified in the same manner as in Example 2 (FIG. 5a).
- the recombinant botulinum toxin light chain protein substituted with the third domain of the botulinum toxin type A3 light chain was not expressed, and the third domain of the botulinum toxin type A6 light chain had the same sequence as the third domain of A1, so it was excluded from the test.
- the third domain of a botulinum toxin type A1 light chain, the third domain of a botulinum toxin type A2 light chain, the third domain of a botulinum toxin type A5 light chain, the third domain of a botulinum toxin type A7 light chain, or the third domain of a botulinum toxin type A8 light chain As a result of substitution with the third domain, the recombinant botulinum toxin type A light chain in which the third domain of the botulinum toxin type A1 light chain was substituted with the third domain of botulinum toxin type A4 had the highest melting point, that is, the best thermal stability (Fig. 5b).
- Example 3 Preparation and purification of domain substituted recombinant botulinum toxin
- the recombinant full-length botulinum toxin gene containing the recombinant botulinum toxin type A light chain with increased thermal stability and increased activity was used with the pMTL80000 vector system. and cloned by infusion method (infusion-HD, Takara).
- the cloned products were named pBT142, pBT143, pBT144, pBT145, pBT146, and pBT147, and the configuration of each domain is shown in a schematic diagram in FIG. 6a.
- a detoxified hall A-hyper strain in which the toxin gene was inactivated using the ClosTron system was prepared and used.
- Detoxified Clostridium botulinum strains including strains in which the toxin gene is inactivated or knocked out, can be used in a method for producing a purified recombinant botulinum toxin or a purified recombinant botulinum toxin complex.
- Methods for preparing strains in which the toxin gene is inactivated or knocked out are known in the art and, for example, using the clostron method is described in Bradshaw et al. 2010, Pellett et al. 2016].
- the recombinant botulinum toxin prepared by the clostron method was purified in the form of 150 kDa without complex components (FIG. 6a).
- Recombinant botulinum toxins were identified as pBT142 (SEQ ID NO: 36), pBT143 (SEQ ID NO: 37), pBT144 (SEQ ID NO: 38), pBT145 (SEQ ID NO: 39), pBT146 (SEQ ID NO: 40), and pBT147 (SEQ ID NO: 41), respectively.
- All of the production of the recombinant botulinum toxin was carried out in facilities licensed for toxin production according to government regulations.
- Test Example 3 Efficacy of recombinant botulinum toxin with domain substitution in rats
- mice Female 6-week-old SD (Sprague-Dawley) rats were purchased from Orient Bio Co., Ltd., and after acclimatization and quarantine for 1 week, 7-week-old rats were used in the experiment.
- sterilized solid feed for laboratory animals R40-10, SAFE, France
- drinking water was freely fed by sterilizing tap water at high temperature and high pressure.
- the mice were set at a temperature of 23 ⁇ 3°C, relative humidity of 55 ⁇ 15%, lighting time of 12 hours (8:00 am to 8:00 pm), ventilation frequency of 15 times/hour, and illumination of 150 to 300 Lux. Raised under specific-pathogen-free conditions. This study was conducted after review and approval by the Medytox Animal Experiment Ethics Committee.
- botulinum toxin type A Lot No.: NSA19016 or NSA20011, Medytox
- Recombinant botulinum toxin pBT142 was prepared at 1316 U/mL and pBT147 at 348 U/mL and used in the experiment.
- the titer of each recombinant botulinum toxin was tested based on the titer value derived by measuring before the efficacy test through the mouse titer test method.
- the efficacy test of recombinant botulinum toxin pBT142 and pBT147, and Coretox was conducted using the same excipient components except for the botulinum toxin component in the recombinant botulinum toxin.
- the dose of each test substance was administered at the same dose based on unit (U: a value representing the biological activity of botulinum toxin, 1U is the mouse half-lethal dose by intraperitoneal administration of a mouse).
- Coretox was diluted using sterile physiological saline (35V3AF3, Daehan Pharmaceutical Co., Ltd.), and recombinant botulinum toxin pBT142 and pBT147 were diluted to concentrations of 12, 40, and 120 U/mL, respectively, using a placebo.
- the day the test substance was administered was set as day 0, and after anesthetizing the rat using an injection anesthetic (60 mg/kg ketamine hydrochloride + 10 mg/kg xylazine), each test substance was administered according to the composition of each group in Table 1. It was administered to the right calf muscle of rats at 0.1 mL/kg using a Hamilton syringe.
- the DAS digital abduction score
- CMAP compound muscle action potential
- the DAS values shown in Table 2 indicate the degree of muscle paralysis by the shape of the toe of the administered side in rats, and the CMAP value indicates the degree of inhibition of direct muscle contraction caused by nerve blockade.
- CMAP was measured in the right calf muscle region of each rat using a Nicolet Viking Quest (Viasys Healthcare, Inc.) instrument. After anesthesia with an injectable anesthetic, hair was shaved at the measurement site, and the rat was placed in a prone position. The cathode was placed on the sciatic nerve on the side of the leg to be measured, and the anode was placed about 1 cm away from the site on the basis of the spine. The recording and reference electrodes were placed on the calf muscle and Achilles tendon, respectively, and the ground electrode was placed on the rectus femoris.
- the level and duration of stimulation were set to 25 ⁇ 30 mA, 0.2 ms, and the filter range of the amplifier was set to 2-10 K at 60 Hz.
- the height from the base to the peak of the waveform was recorded as CMAP measurement values.
- the DAS measurements for comparing the effects of pBT142 and Coretox in Experiment 1 were 1.2, 4, It was evaluated from day 1 to day 112 after administration at a dose of 12 U/kg, and CMAP measurements were measured from day 8 to day 127 after administration in subjects administered at a dose of 12 U/kg.
- DAS measurements were evaluated from 1 day to 112 days after administration at doses of 1.2, 4, and 12 U/kg, and CMAP measurements were performed on individuals administered at 12 U/kg doses. Measurements were taken from day 0 to day 126 after administration in the field.
- Graphpad Prism 7.05 (GraphPad Software Inc., CA, USA) was used for graph presentation and SPSS software 25.0 (SPSS Inc., IL, USA) and Excel (2013, MS, USA) were used for statistical analysis. Results of experiments are expressed as mean ⁇ standard deviation.
- DAS ED 50 was calculated using a 3-parameter logistic model after fixing the lowest 0-point and highest 4-point values using Graphpad Prism. Normality test was performed using the Kolmogorov-Smirnov test. Non-parametric data was analyzed statistically through the Mann-Whitney test, and in the case of parametric data, a two-tailed t -test was performed and statistical significance was determined when the p -value was less than 0.05.
- the group administered with Coretox 1.2 U/kg all individuals recovered on day 28, and in the group administered with the same dose of pBT147, all individuals recovered on day 35, an increase of 7 days.
- Test Example 4 Efficacy of recombinant botulinum toxin with domain substitution in mice
- mice 5-week-old female CD1 (ICR) mice were purchased from Orient Bio Co., Ltd., and after acclimatization and quarantine for 1 week, 6-week-old mice were used in the experiment.
- For the feed sterilized solid feed for laboratory animals (R40-10, SAFE, France) was freely fed, and for drinking water, tap water was sterilized at high temperature and high pressure.
- the mice were set at a temperature of 23 ⁇ 3°C, relative humidity of 55 ⁇ 15%, lighting time of 12 hours (8:00 am to 8:00 pm), ventilation frequency of 15 times/hour, and illumination of 150 to 300 Lux. Breeding was carried out under specific-pathogen-free conditions. This study was conducted after review and approval by the Medytox Animal Experiment Ethics Committee.
- Coretox was diluted using sterile physiological saline (35V3AF3, Daehan Pharmaceutical), and recombinant botulinum toxin pBT142 and pBT147 were diluted to concentrations of 6, 20, 60, and 200 U/mL using a placebo, respectively.
- Day 0 was the day the test substance was administered, and after anesthetizing the mouse using an injection anesthetic (100 mg/kg ketamine hydrochloride + 10 mg/kg xylazine), each test substance was administered to the right calf muscle of the mouse according to the group composition in Table 3. was administered at 0.2 mL/kg using a Hamilton syringe.
- the evaluation used a DAS (digit abduction score) evaluation method that visually evaluates the degree of mouse muscle paralysis and a compound muscle action potential (CMAP) test method that measures the action potential of muscles in response to external electrical stimulation.
- DAS digital abduction score
- CMAP compound muscle action potential
- CMAP was measured in the right calf muscle region of each mouse using a Nicolet Viking Quest (Viasys Healthcare, Inc.) instrument.
- the measurement method is the same as in Test Example 3 except for the stimulation level and duration of 7-8 mA and 0.1 ms.
- DAS measurement was performed at doses of 1.2, 4, 12, and 40 U/kg.
- the dose was evaluated from day 1 to day 84 after administration, and CMAP measurement was measured from the day of administration to day 98 in subjects administered at a dose of 12 U/kg, and statistically processed in the same manner as in Test Example 3.
- the terms 'protein' and 'polypeptide' are used interchangeably herein to mean polymers of amino acid residues and variants and synthetic analogues thereof. These terms apply to naturally occurring amino acid polymers, including non-naturally occurring amino acids in which one or more amino acid residues are synthesized, e.g., chemical analogues of related naturally occurring amino acids. These terms also include post-translational modifications of polypeptides, such as glycosylation, phosphorylation and acetylation.
- Botulinum toxin encompasses any polypeptide or fragment of a botulinum toxin.
- botulinum toxin refers to full-length botulinum toxin or botulinum toxin derived fragments.
- a botulinum toxin is capable of entering a neuron and executing a global cellular mechanism that inhibits neurotransmitter release.
- domain' is a tertiary structure that can exist and evolve independently of the rest of the protein chain as a conserved portion of a given protein sequence. Because the domains are independently stable, domains can be swapped by genetic engineering between one protein and another to create chimeric proteins.
- the term 'percent identity' refers to the degree of amino acid sequence identity between polypeptides. For example, when a first amino acid sequence is identical to a second amino acid sequence, the first and second amino acid sequences exhibit 100% identity.
- the percent identity of the two amino acid sequences can be found in Karlin and Altschul Proc. Natl. Acad. Sci. USA 87:2264-68, 1990, Karlin and Altschul Proc. Natl. Acad. Sci. USA 90:5873-77, 1993 can be determined using a modified allorhythm. Such an algorithm is described in Altschul, et al. J. Mol. Biol. 215:403-10, 1990 in the NBLAST and XBLAST programs (version 2.0).
- 'recombination' refers to a process in which elements constituting genes such as DNA (Deoxyribonucleic Acid) or RNA (Ribonucleic Acid) are reversed differently from the original sequence during disassembly and reassembly.
- DNA Deoxyribonucleic Acid
- RNA Ribonucleic Acid
- the term 'variant' encompasses, ie, any modification in a nucleic acid or amino acid sequence, eg, truncations, additions, deletions, substitutions of nucleic acids or amino acids, and any combination thereof. That is, the 'variant of the recombinant botulinum toxin type A light chain domain' may include truncation, addition, deletion, substitution of nucleic acids or amino acids constituting the recombinant botulinum neurotoxin type A light chain domain, and any combination thereof.
- substitutions may include any amino acid other than the wild-type residue normally found at any sequence position. Such substitutions may be with non-polar (hydrophobic) amino acids such as glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, and proline. Substitutions can be with polar (hydrophilic) amino acids such as serine, threonine, cysteine, tyrosine, asparagine, and glutamine. Substitutions can be with electrically charged amino acids such as negatively charged amino acids such as aspartic acid and glutamic acid and positively charged amino acids such as lysine, arginine, and histidine.
- non-polar (hydrophobic) amino acids such as glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, and proline.
- substitutions can be with polar (hydrophilic) amino acids
- wild type' refers to a common species phenotype that occurs in nature.
- the wild type may be the product of the canonical normal allele at the locus as opposed to that produced by the non-canonical mutant allele.
- the term 'subject' may be male or female.
- An individual may be a fully developed individual (eg, an adult) or an individual undergoing a developmental process (eg, a child, infant, or fetus).
- the subject may be a mammal.
- a mammal can be, but is not limited to, a human, non-human primate, mouse, rat, dog, cat, horse, or cow.
- botulinum toxin preparations Most of the botulinum toxin preparations currently on the market are preparations in which the active ingredient is botulinum toxin type A1, and in the case of Myobloc, botulinum toxin type B1 is used as an active ingredient. It is known that the duration of efficacy of botulinum toxin type A1 preparations is about 3 months on average, and shorter in the case of botulinum toxin type B1 preparations. Due to the nature of botulinum toxin preparations that must be administered by intramuscular injection, it is necessary to develop products that have a longer duration than commercially available preparations in terms of patient convenience.
- the present inventors divided the sequences of botulinum toxin type A1 and A4 light chains into first, second, third, and fourth domains according to the domain characteristics of FIG. 2, as shown in FIG. 1, into a total of four domains.
- the first domain (SEQ ID NO: 1) of the botulinum toxin type A1 light chain and the first domain (SEQ ID NO: 5) of the A4 light chain are sites that interact with SNAP25, a substrate, and contain ⁇ -exosite.
- the first domain of the botulinum toxin type A1 and A4 light chain comprises amino acids from position 1 to amino acids from positions 90 to 150 (e.g., positions 90, 95, 100, 105, 110, 115, 120). , amino acids at positions 125, 130, 135, 140, 145, and 150).
- the second domain (SEQ ID NO: 2) of the botulinum toxin type A1 light chain and the second domain (SEQ ID NO: 6) of the A4 light chain are parts mainly involved in the enzymatic activity of the light chain, and contain 170 loops, and contain zinc and part that connects.
- the second domain of botulinum toxin type A1 and A4 light chain comprises amino acids at positions 91-151 (e.g., positions 91, 96, 101, 106, 111, 116, 121, 126, 131).
- amino acids at positions 136, 141, 146, and 151 amino acids at positions 136, 141, 146, and 151) to amino acids at positions 210 to 270 (e.g., positions 210, 215, 220, 225, 230, 235, 240, amino acids at positions 245, 250, 255, 260, 265, and 270).
- the third domain (SEQ ID NO: 3) of the botulinum toxin type A1 light chain and the third domain (SEQ ID NO: 7) of the A4 light chain contain 250 loops and 370 loops for stabilizing substrate binding and substrate binding. It is a site involved in both ⁇ -exosite and ⁇ -exosite.
- the third domain of the botulinum toxin type A1 and A4 light chain comprises amino acids 211-271 (e.g., 211, 216, 221, 226, 231, 236, 241, 246, 251, 256 261, 266 and 271 amino acids) to amino acids 386-446 (e.g., 386, 391, 396, 401, 406, 411, 416, 421, 426, 431 436, 441, and 446 amino acids).
- amino acids 211-271 e.g., 211, 216, 221, 226, 231, 236, 241, 246, 251, 256 261, 266 and 271 amino acids
- amino acids 386-446 e.g., 386, 391, 396, 401, 406, 411, 416, 421, 426, 431 436, 441, and 446 amino acids.
- the fourth domain (SEQ ID NO: 4) of the botulinum toxin type A1 light chain and the fourth domain (SEQ ID NO: 8) of the A4 light chain are parts involved in the structural flexibility of the botulinum toxin type A light chain.
- the fourth domain of the botulinum toxin type A1, and A4 light chain is amino acids 362-425 (e.g., 362, 367, 372, 377, 382, 387, 392, 397, 402, 407 amino acids 412, 417, 422 and 425) to amino acids 410 to 448 (e.g., 410, 414, 417, 420, 425, 430, 435, 440, 445). 1, and amino acids 448).
- the sequence of the third domain among the first, second, third, and fourth domains of a botulinum toxin type A light chain other than botulinum toxin type A4 is the third domain of a botulinum toxin type A4 light chain or a variant thereof.
- the botulinum toxin type A light chain other than botulinum toxin type A4 is a botulinum toxin type A1 light chain (SEQ ID NO: 9), a botulinum toxin type A2 light chain (SEQ ID NO: 10), a botulinum toxin type A3 light chain (SEQ ID NO: 11) , botulinum toxin type A5 light chain (SEQ ID NO: 13), botulinum toxin type A6 light chain (SEQ ID NO: 14), botulinum toxin type A7 light chain (SEQ ID NO: 15) or botulinum toxin type A8 light chain (SEQ ID NO: 16).
- a botulinum toxin type A light chain can be a botulinum toxin type A1 light chain.
- the third domain of the botulinum toxin type A4 light chain may be the sequence of SEQ ID NO: 7.
- the variant of the third domain of the botulinum toxin type A4 light chain is involved in both ⁇ -exosite and ⁇ -exosite, which are substrate binding sites, identically to the third domain of the botulinum toxin type A4 light chain, and has the sequence of SEQ ID NO: 3 and amino acid sequences having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity; include
- the sequence of the fourth domain among the first, second, third, and fourth domains of the recombinant botulinum toxin type A light chain is added to the sequence of the fourth domain of the botulinum toxin type A4 light chain or a variant thereof.
- a recombinant botulinum toxin type A light chain is provided.
- the fourth domain of the botulinum toxin type A4 light chain may be the sequence of SEQ ID NO: 8.
- the variant of the fourth domain of the botulinum toxin type A4 light chain is involved in the structural flexibility of the botulinum toxin type A light chain identically to the fourth domain of the botulinum toxin type A4 light chain and is at least 90%, at least 91% identical to SEQ ID NO: 4. %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity.
- a recombinant botulinum toxin comprising the recombinant botulinum toxin type A light chain and the botulinum toxin heavy chain is provided.
- the botulinum toxin heavy chain is a botulinum toxin type A heavy chain, a botulinum toxin type B heavy chain, a botulinum toxin type C heavy chain, a botulinum toxin type D heavy chain, a botulinum toxin type E heavy chain, a botulinum toxin type F heavy chain, or a botulinum toxin. It may be a type G heavy chain.
- the botulinum toxin heavy chain may be a botulinum toxin type A heavy chain.
- a botulinum toxin heavy chain is a botulinum toxin type A1 heavy chain, a botulinum toxin type A2 heavy chain, a botulinum toxin type A3 heavy chain, a botulinum toxin type A4 heavy chain, a botulinum toxin type A5 heavy chain, a botulinum toxin type A6 heavy chain, a botulinum toxin type A7 heavy chain, or It may be a botulinum toxin type A8 heavy chain.
- the botulinum toxin heavy chain can be a botulinum toxin type A1 heavy chain (SEQ ID NO: 17).
- the recombinant botulinum toxin may be a recombinant botulinum toxin in which a recombinant botulinum toxin type A light chain and a botulinum toxin heavy chain are linked by a disulfide bond.
- recombinant botulinum toxin is produced in Clostridium bacteria as a single, relatively inactive polypeptide chain weighing about 150 kDa with a high degree of amino acid sequence identity between botulinum toxin types. The single polypeptide then breaks down into an approximately 100 kDa heavy chain and a 50 kDa light chain, and the heavy and light chains can form disulfide bonds.
- composition comprising the recombinant botulinum toxin and a pharmaceutically acceptable excipient or additive is provided.
- the pharmaceutically acceptable excipient or additive is a stabilizer, an ionic compound, a surfactant, a buffer, a lyophilization protectant, or a combination thereof such as an amino acid (eg methionine), a salt (e.g. NaCl), buffers, non-ionic surfactants (e.g. polysorbates, e.g. polysorbate 20), sugars (e.g. disaccharides such as sucrose, etc.), sugar alcohols (e.g. sorbitol ), or a combination thereof.
- an amino acid eg methionine
- a salt e.g. NaCl
- non-ionic surfactants e.g. polysorbates, e.g. polysorbate 20
- sugars e.g. disaccharides such as sucrose, etc.
- sugar alcohols e.g. sorbitol
- the composition may be one that does not contain albumin or animal-derived components.
- compositions that do not contain albumin or animal-derived components include those disclosed in WO2009-008595A1 or WO2012-134240A2, the contents of which are incorporated herein by reference in their entirety.
- the composition may be formulated in any form, such as a solid or liquid formulation, for example, a lyophilized powder, liquid, or pre-filled syringe formulation.
- composition comprising the recombinant botulinum toxin and a pharmaceutically acceptable excipient or additive is administered to a subject to ameliorate or treat a disease.
- a composition containing the recombinant botulinum toxin, pharmaceutically acceptable excipients or additives is administered to a subject to treat wrinkles, square jaws, pointed chins, scars, skin softening, scars, acne, pores, elasticity or keloids. It may be used for improvement.
- a composition comprising the recombinant botulinum toxin, pharmaceutically acceptable excipients or additives is administered to a subject to treat facial spasms, blepharospasm, torticollis, blepharospasm, cervical dystonia, central pharyngeal dystonia, spastic dysphonia , migraine, pruritus anus or hyperhidrosis.
- the composition may be administered by transdermal, subcutaneous, or intramuscular administration. In an embodiment, it may be by topically administering the composition to a muscle or group of muscles. In embodiments, the reduction of forehead wrinkles and skin wrinkles can be achieved by transdermal or subcutaneous administration of the composition to the wrinkles.
- a method for ameliorating or treating a disease by administering to a subject a composition further comprising the recombinant botulinum toxin and a pharmaceutically acceptable excipient or additive is provided.
- it may be a method for improving wrinkles, square jaws, pointed jaws, scars, skin softening, scars, acne, pores, elasticity, or keloids, comprising administering the composition to a subject.
- treating facial spasm, blepharospasm, torticollis, blepharospasm, cervical dystonia, oropharyngeal dystonia, spasmodic dysphonia, migraine, pruritus ani or hyperhidrosis, comprising administering the composition to a subject. may be a way to
- the sequence of the third domain among the first, second, third, and fourth domains of the botulinum toxin type A light chain, other than botulinum toxin type A4, is the third domain of botulinum toxin type A4 or a variant thereof.
- a method for producing a recombinant botulinum toxin type A light chain having increased potency or half-life compared to wild-type botulinum toxin type A1 light chain comprising the step of substituting the sequence of
- an increased potency compared to a wild-type botulinum toxin type A1 light chain comprising replacing the sequence of the third domain of the botulinum toxin type A1 light chain with the sequence of the third domain of botulinum toxin type A4 or a variant thereof; It may be a method for preparing a recombinant botulinum toxin type A light chain having a half-life.
- preparing a recombinant botulinum toxin A light chain (pBT103, SEQ ID NO: 19) in which the sequence of the third domain of the botulinum toxin type A1 light chain is replaced with the sequence of the third domain of the botulinum toxin type A4 or a variant thereof. may be a method for producing a recombinant botulinum toxin type A light chain having an increased potency or half-life compared to wild-type botulinum toxin.
- the sequence of the fourth domain among the first, second, third, and fourth domains of the recombinant botulinum toxin type A light chain is added to the sequence of the fourth domain of botulinum toxin type A4 or a variant thereof.
- the sequence of the fourth domain of the recombinant botulinum toxin type A light chain is increased compared to wild-type botulinum toxin type A1, comprising further replacing the sequence of the fourth domain of botulinum toxin type A4 or a variant thereof. It may be a method for preparing a recombinant botulinum toxin type A light chain having a reduced potency or half-life.
- botulinum toxin type A1 light chain and botulinum toxin type A4 light chain genes replacing four domains of botulinum toxin type A1 light chain and botulinum toxin type A4 light chain genes with each other; Genes containing the wild-type botulinum toxin type A light chain and the domain-substituted recombinant botulinum toxin type A light chain were respectively cloned and introduced into E. coli to induce expression of the domain-substituted recombinant botulinum toxin type A light chain.
- the recombinant botulinum toxin A light chain (pBT104, sequence) in which the sequences of the third domain and the fourth domain of the botulinum toxin type A1 light chain are substituted with sequences of the third domain, the fourth domain or a variant thereof of the botulinum toxin type A4.
- No. 20 may be a method for preparing a recombinant botulinum toxin type A light chain having an increased potency or half-life compared to wild-type botulinum toxin type A1.
- Another aspect of the present disclosure provides a cell comprising a polynucleotide encoding the recombinant botulinum toxin type A light chain and a nucleic acid comprising the polynucleotide encoding the botulinum toxin heavy chain or a vector comprising the same.
- the cell may express a recombinant botulinum toxin including the recombinant botulinum toxin type A light chain and the botulinum toxin heavy chain.
- culturing a cell comprising a polynucleotide encoding the recombinant botulinum toxin type A light chain and a nucleic acid comprising the polynucleotide encoding the botulinum toxin heavy chain or a vector comprising the same
- a method for producing a recombinant botulinum toxin having an increased potency or half-life compared to wild-type botulinum toxin may further include isolating the recombinant botulinum toxin from the culture.
- the botulinum toxin heavy chain is a botulinum toxin type A1 heavy chain, a botulinum toxin type A2 heavy chain, a botulinum toxin type A3 heavy chain, a botulinum toxin type A4 heavy chain, a botulinum toxin type A5 heavy chain, a botulinum toxin type A6 heavy chain, a botulinum toxin type A7 heavy chain or a botulinum toxin type A8 heavy chain.
- the botulinum toxin heavy chain can be a botulinum toxin type A1 heavy chain (SEQ ID NO: 17).
- cloning a full-length recombinant botulinum toxin gene comprising a domain-substituted recombinant botulinum toxin type A light chain (pBT103, pBT104) and a botulinum toxin type A1 heavy chain;
- the cloned toxin gene is introduced into an inactivated, detoxified strain, and the inactivated, detoxified strain into which the toxin gene is introduced is cultured to prepare a botulinum toxin with a domain substitution [Bradshaw et al. 2010, Pellett et al.
- It may be a method for preparing a recombinant botulinum toxin having an increased potency or half-life compared to wild-type botulinum toxin, comprising purifying and isolating a 150 kDa recombinant toxin without complex components from the culture.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Wood Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
군 | 동물수 | 투여물질 | 용량 (U/kg) | 투여경로 | 평가지표 | |
실험1 | 1 | 6 | 플라시보 | 0 | 우측 장딴지근육 | DAS, CMAP |
2 | 6 | 코어톡스 | 1.2 | 우측 장딴지근육 | DAS | |
3 | 6 | 코어톡스 | 4 | 우측 장딴지근육 | DAS | |
4 | 6 | 코어톡스 | 12 | 우측 장딴지근육 | DAS, CMAP | |
5 | 6 | pBT142 | 1.2 | 우측 장딴지근육 | DAS | |
6 | 6 | pBT142 | 4 | 우측 장딴지근육 | DAS | |
7 | 6 | pBT142 | 12 | 우측 장딴지근육 | DAS, CMAP | |
실험2 | 1 | 6 | 플라시보 | 0 | 우측 장딴지근육 | DAS, CMAP |
2 | 6 | 코어톡스 | 1.2 | 우측 장딴지근육 | DAS | |
3 | 6 | 코어톡스 | 4 | 우측 장딴지근육 | DAS | |
4 | 6 | 코어톡스 | 12 | 우측 장딴지근육 | DAS, CMAP | |
5 | 6 | pBT147 | 1.2 | 우측 장딴지근육 | DAS | |
6 | 6 | pBT147 | 4 | 우측 장딴지근육 | DAS | |
7 | 6 | pBT147 | 12 | 우측 장딴지근육 | DAS, CMAP |
점수 | 기준 |
0 | 정상 |
1 | 다섯번째 발가락의 외전 소실 |
2 | 세개의 발가락이 서로 붙어있음 |
3 | 네개의 발가락이 서로 붙어있음 |
4 | 모든 발가락의 외전 소실 및 서로 붙어있음 |
군 | 동물수 | 투여물질 | 용량 (U/kg) | 투여경로 | 평가지표 |
1 | 6 | 플라시보 | 0 | 우측 장딴지근육 | DAS, CMAP |
2 | 6 | 코어톡스 | 1.2 | 우측 장딴지근육 | DAS |
3 | 6 | 코어톡스 | 4 | 우측 장딴지근육 | DAS |
4 | 6 | 코어톡스 | 12 | 우측 장딴지근육 | DAS, CMAP |
5 | 6 | 코어톡스 | 40 | 우측 장딴지근육 | DAS |
6 | 6 | pBT142 | 1.2 | 우측 장딴지근육 | DAS |
7 | 6 | pBT142 | 4 | 우측 장딴지근육 | DAS |
8 | 6 | pBT142 | 12 | 우측 장딴지근육 | DAS, CMAP |
9 | 6 | pBT142 | 40 | 우측 장딴지근육 | DAS |
10 | 6 | pBT147 | 1.2 | 우측 장딴지근육 | DAS |
11 | 6 | pBT147 | 4 | 우측 장딴지근육 | DAS |
12 | 6 | pBT147 | 12 | 우측 장딴지근육 | DAS, CMAP |
13 | 6 | pBT147 | 40 | 우측 장딴지근육 | DAS |
점수 | 기준 |
0 | 정상, 주입하지 않은 쪽의 발 모양과 다르지 않음 |
1 | 발가락 사이의 넓이가 좁하져 있음, 또는 두 개의 발가락이 서로 붙어 있고 나머지는 완전히 펴짐 |
2 | 모든 발가락 사이가 상당히 좁아져 있음, 또는 세 개의 발가락이 서로 붙어 있음 |
3 | 발이 굽어 있고 네 개의 발가락이 서로 붙어 있음 |
4 | 발이 굽어 있고 모든 발가락이 서로 붙어 있음 |
Claims (28)
- 보툴리눔 독소 타입 A4가 아닌 보툴리눔 독소 타입 A 경쇄의 제 1, 2, 3, 및 4 도메인 중 제 3 도메인의 서열이, 보툴리눔 독소 타입 A4의 제3 도메인 또는 그의 변이체의 서열로 치환된 것인, 재조합 보툴리눔 독소 타입 A 경쇄.
- 제1항에 있어서, 재조합 보툴리눔 독소 타입 A 경쇄의 제 1, 2, 3, 및 4 도메인 중 제 4 도메인의 서열이, 보툴리눔 독소 타입 A4의 제 4 도메인 또는 그 변이체의 서열로 추가로 치환된 것인, 재조합 보툴리눔 독소 타입 A 경쇄.
- 제1항 또는 제2항에 있어서, 보툴리눔 독소 타입 A 경쇄는 보툴리눔 독소 타입 A1, A2, A3, A5, A6, A7 또는 A8인 것인, 재조합 보툴리눔 독소 타입 A 경쇄.
- 제3항에 있어서, 보툴리눔 독소 타입 A 경쇄는 보툴리눔 독소 타입 A1인 것인, 재조합 보툴리눔 독소 타입 A 경쇄.
- 제1항 내지 제4항 중 어느 한 항의 재조합 보툴리눔 독소 타입 A 경쇄, 및 보툴리눔 독소 중쇄를 포함하는 것인, 재조합 보툴리눔 독소.
- 제5항에 있어서, 보툴리눔 독소 타입 A 중쇄는 보툴리눔 독소 타입 A, B, C, D, E, F, 또는 G인 것인, 재조합 보툴리눔 독소.
- 제6항에 있어서, 보툴리눔 독소 타입 A 중쇄는 보툴리눔 독소 타입 A1, A2, A3, A4, A5, A6, A7 또는 A8인 것인, 재조합 보툴리눔 독소.
- 제7항에 있어서, 보툴리눔 독소 타입 A 중쇄는 보툴리눔 독소 타입 A1인 것인, 재조합 보툴리눔 독소.
- 제5항 내지 제8항 중 어느 한 항의 재조합 보툴리눔 독소 타입 A, 및 약제학적으로 허용되는 부형제 또는 첨가제를 포함하는 조성물.
- 제9항에 있어서, 약제학적으로 허용되는 부형제 또는 첨가제는 안정화제, 이온화합물, 계면활성제, 완충제, 동결건조 보호제, 또는 이들의 조합인 조성물.
- 제10항에 있어서, 약제학적으로 허용되는 부형제 또는 첨가제는 아미노산, 염, 완충액, 비이온성 계면활성제, 당, 당 알코올, 또는 이들의 조합인 조성물.
- 제9항 내지 제11항 중 어느 한 항에 있어서, 알부민 또는 동물 유래 성분을 포함하지 않는 조성물.
- 제9항 내지 제12항 중 어느 한 항에 있어서, 동결건조 분말, 액상, 또는 프리필드 시린지 제제 형태의 조성물.
- 제9항 내지 제13항 중 어느 한 항에 있어서, 주름살, 사각턱, 뾰쪽턱, 상처, 피부연화, 흉터, 여드름, 모공, 탄력 또는 켈로이드 증상을 개선하기 위한 조성물.
- 제9항 내지 제13항 중 어느 한 항에 있어서, 안면경련, 눈꺼풀 경련, 사경, 안검경련, 경부 근긴장 이상증, 인두 중앙부 근긴장 이상증, 경련성 발성 장애, 편두통, 항문 소양증 또는 다한증을 치료하기 위한 조성물.
- 제9항 내지 제15항 중 어느 한 항에 있어서, 경피, 피하, 또는 근육내 투여용인 조성물.
- 주름살, 사각턱, 뾰쪽턱, 상처, 피부연화, 흉터, 여드름, 모공, 탄력 또는 켈로이드 증상을 개선하기 위한, 제9항 내지 제13항 중 어느 한 항에 따른 조성물의 용도.
- 안면경련, 눈꺼풀 경련, 사경, 안검경련, 경부 근긴장 이상증, 인두 중앙부 근긴장 이상증, 경련성 발성 장애, 편두통, 항문 소양증 또는 다한증을 치료하기 위한, 제9항 내지 제13항 중 어느 한 항에 따른 조성물의 용도.
- 제9항 내지 제13항 중 어느 한 항의 조성물을 개체에 투여하는 단계를 포함하는, 주름살, 사각턱, 뾰쪽턱, 상처, 피부연화, 흉터, 여드름, 모공, 탄력 또는 켈로이드를 개선하기 위한 방법.
- 제9항 내지 제13항 증 어느 한 항의 조성물을 개체에 투여하는 단계를 포함하는, 안면경련, 눈꺼풀 경련, 사경, 안검경련, 경부 근긴장 이상증, 인두 중앙부 근긴장 이상증, 경련성 발성 장애, 편두통, 항문 소양증 또는 다한증을 치료하기 위한 방법.
- 보툴리눔 독소 타입 A4가 아닌 보툴리눔 독소 타입 A 경쇄의 제 1, 2, 3, 및 4 도메인 중 제 3 도메인의 서열이, 보툴리눔 독소 타입 A4의 제 3 도메인 또는 그 변이체의 서열로 치환되는 단계를 포함하는, 야생형 보툴리눔 독소 타입 A 경쇄 대비 증가된 효력 또는 반감기를 갖는 재조합 보툴리눔 독소 타입 A 경쇄를 제조하는 방법.
- 제21항에 있어서, 재조합 보툴리눔 독소 타입 A 경쇄의 제 1, 2, 3, 및 4 도메인 중 제 4 도메인의 서열이, 보툴리눔 독소 타입 A4의 제 4 도메인 또는 그 변이체의 서열로 추가로 치환되는 단계를 포함하는, 야생형 보툴리눔 독소 타입 A 경쇄 대비 증가된 효력 또는 반감기를 갖는 재조합 보툴리눔 독소 타입 A 경쇄를 제조하는 방법.
- 제21항 또는 제22항에 있어서, 보툴리눔 독소 타입 A 경쇄는 보툴리눔 독소 타입 A1, A2, A3, A5, A6, A7 또는 A8인 것인, 야생형 보툴리눔 독소 타입 A 경쇄 대비 증가된 효력 또는 반감기를 갖는 재조합 보툴리눔 독소 타입 A 경쇄를 제조하는 방법.
- 제23항에 있어서, 보툴리눔 독소 타입 A 경쇄는 보툴리눔 독소 타입 A1인 것인, 야생형 보툴리눔 독소 타입 A 경쇄 대비 증가된 효력 또는 반감기를 갖는 재조합 보툴리눔 독소 타입 A 경쇄를 제조하는 방법.
- 제1항 내지 제4항 중 어느 한 항의 재조합 보툴리눔 독소 타입 A 경쇄를 코딩하는 폴리뉴클레오티드, 및 보툴리눔 독소 중쇄를 코딩하는 폴리뉴클레오티드를 포함하는 핵산 분자 또는 이를 포함하는 벡터를 포함하는 세포를 배양하는 단계를 포함하는, 야생형 보툴리눔 독소 대비 증가된 효력 또는 반감기를 갖는 재조합 보툴리눔 독소를 제조하는 방법.
- 제25항에 있어서, 보툴리눔 독소 중쇄는 보툴리눔 독소 타입 A, B, C, D, E, F, 또는 G인 것인, 야생형 보툴리눔 독소 대비 증가된 효력 또는 반감기를 갖는 재조합 보툴리눔 독소를 제조하는 방법.
- 제26항에 있어서, 보툴리눔 독소 중쇄는 보툴리눔 독소 타입 A1, A2, A3, A4, A5, A6, A7 또는 A8인 것인, 야생형 보툴리눔 독소 대비 증가된 효력 또는 반감기를 갖는 재조합 보툴리눔 독소를 제조하는 방법.
- 제27항에 있어서, 보툴리눔 독소 중쇄는 보툴리눔 독소 타입 A1인 것인, 야생형 보툴리눔 독소 대비 증가된 효력 또는 반감기를 갖는 재조합 보툴리눔 독소를 제조하는 방법.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280046503.5A CN117580854A (zh) | 2021-06-28 | 2022-06-21 | 重组a型肉毒毒素轻链、重组肉毒毒素、以及其组合物、用途和方法 |
EP22833488.4A EP4365190A1 (en) | 2021-06-28 | 2022-06-21 | Recombinant botulinum toxin type a light chain, recombinant botulinum toxin, and composition, use, and method thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0083930 | 2021-06-28 | ||
KR1020210083930A KR20230001254A (ko) | 2021-06-28 | 2021-06-28 | 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023277432A1 true WO2023277432A1 (ko) | 2023-01-05 |
Family
ID=84692845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/008793 WO2023277432A1 (ko) | 2021-06-28 | 2022-06-21 | 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4365190A1 (ko) |
KR (1) | KR20230001254A (ko) |
CN (1) | CN117580854A (ko) |
WO (1) | WO2023277432A1 (ko) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009008595A1 (en) | 2007-07-10 | 2009-01-15 | Medy-Tox, Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
WO2012134240A2 (ko) | 2011-03-31 | 2012-10-04 | (주)메디톡스 | 보툴리눔 독소의 동결건조제제 |
WO2017214447A1 (en) | 2016-06-08 | 2017-12-14 | Children's Medical Center Corporation | Engineered botulinum neurotoxins |
EP3335719A1 (en) * | 2016-12-14 | 2018-06-20 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with a stabilized light chain |
US20180193435A1 (en) * | 2017-01-10 | 2018-07-12 | Cellsnap Llc | Hybrid neurotoxins and uses thereof |
KR20180130452A (ko) * | 2017-05-29 | 2018-12-07 | 바이오위더스 주식회사 | 고용해성 녹색형광 단백질과 보툴리늄 독소 단백질의 융합단백질 구성을 통한 재조합 보툴리늄 독소 단백질의 대량생산 기술 |
KR20200024734A (ko) * | 2018-08-28 | 2020-03-09 | 성균관대학교산학협력단 | 신경세포 표적용 단백질 조성물 |
KR20200031143A (ko) * | 2017-07-21 | 2020-03-23 | 상하이테크 유니버시티 | 국소 조성물 및 용도 |
-
2021
- 2021-06-28 KR KR1020210083930A patent/KR20230001254A/ko unknown
-
2022
- 2022-06-21 CN CN202280046503.5A patent/CN117580854A/zh active Pending
- 2022-06-21 WO PCT/KR2022/008793 patent/WO2023277432A1/ko active Application Filing
- 2022-06-21 EP EP22833488.4A patent/EP4365190A1/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009008595A1 (en) | 2007-07-10 | 2009-01-15 | Medy-Tox, Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
WO2012134240A2 (ko) | 2011-03-31 | 2012-10-04 | (주)메디톡스 | 보툴리눔 독소의 동결건조제제 |
WO2017214447A1 (en) | 2016-06-08 | 2017-12-14 | Children's Medical Center Corporation | Engineered botulinum neurotoxins |
EP3335719A1 (en) * | 2016-12-14 | 2018-06-20 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with a stabilized light chain |
US20180193435A1 (en) * | 2017-01-10 | 2018-07-12 | Cellsnap Llc | Hybrid neurotoxins and uses thereof |
WO2018132423A1 (en) | 2017-01-10 | 2018-07-19 | Cellsnap Llc | Hybrid neurotoxins and uses thereof |
KR20180130452A (ko) * | 2017-05-29 | 2018-12-07 | 바이오위더스 주식회사 | 고용해성 녹색형광 단백질과 보툴리늄 독소 단백질의 융합단백질 구성을 통한 재조합 보툴리늄 독소 단백질의 대량생산 기술 |
KR20200031143A (ko) * | 2017-07-21 | 2020-03-23 | 상하이테크 유니버시티 | 국소 조성물 및 용도 |
KR20200024734A (ko) * | 2018-08-28 | 2020-03-09 | 성균관대학교산학협력단 | 신경세포 표적용 단백질 조성물 |
Non-Patent Citations (4)
Title |
---|
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10 |
ALTSCHUL ET AL., NUCLEIC ACIDS RES, vol. 25, no. 17, 1997, pages 3389 - 3402 |
KARLINALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 68 |
KARLINALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 77 |
Also Published As
Publication number | Publication date |
---|---|
EP4365190A1 (en) | 2024-05-08 |
CN117580854A (zh) | 2024-02-20 |
KR20230001254A (ko) | 2023-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230285521A1 (en) | Composition comprising recombinant clostridium neurotoxin | |
KR101942106B1 (ko) | 분해가능한 클로스트리듐 독소 | |
TWI776147B (zh) | 陽離子型神經毒素 | |
US8273358B2 (en) | Activatable clostridial toxins | |
WO2018038301A1 (en) | Stabilized liquid formulation of botulinum toxin and preparation method thereof | |
WO2015016462A1 (en) | Method for production of botulinum toxin | |
ES2930237T3 (es) | Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos | |
US20160166656A1 (en) | Compositions and Methods for Treating Celiac Sprue Disease | |
WO2012050402A2 (ko) | 세포투과성 parkin 재조합 단백질 및 이를 함유하는 퇴행성 뇌질환 치료용 약학적 조성물 | |
US11952601B2 (en) | Recombinant botulinum toxin with increased duration of effect | |
US20170204391A1 (en) | Method for the manufacturing of di-chain proteins for use in humans | |
WO2020060128A1 (ko) | 세포 침투 효과가 우수한 보툴리늄 유래 펩타이드를 포함하는 화장료 조성물 | |
TW201718627A (zh) | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 | |
US20200354706A1 (en) | Novel recombinant botulinum toxin with increased duration of effect | |
WO2018038585A1 (ko) | 보툴리눔 독소 및 안정화제를 포함하는 액상 제형 및 이의 제조방법 | |
WO2023277432A1 (ko) | 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법 | |
WO2023277433A1 (ko) | 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법 | |
WO2019004674A1 (ko) | 아세틸콜린수용체 결합 펩타이드 | |
WO2019164134A1 (ko) | 보툴리눔 독소, 안정화제, 및 국소마취제를 포함하는 액상 제형 및 이의 제조방법 | |
WO2021125866A1 (ko) | 보툴리눔 신경 독소의 안전한 제조 방법 | |
US9623075B2 (en) | Type A2 botulinum toxin preparation | |
WO2023172101A1 (ko) | 광유전학적으로 활성화 가능한 팔미토일화 조절 단백질 및 이의 용도 | |
WO2022260468A1 (ko) | 신규 fgf21 변이체 개발 및 이의 생산기법과 용도 | |
WO2023239229A1 (ko) | 보툴리눔 독소 안정화 조성물, 이를 포함하는 보툴리눔 독소 제제 및 이에 사용하기 위한 폴리펩티드 | |
WO2023080718A1 (ko) | 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22833488 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023580789 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280046503.5 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022833488 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022833488 Country of ref document: EP Effective date: 20240129 |